# Sirolimus Treatment for Refractory PRCA

> **NCT03364764** · PHASE4 · COMPLETED · sponsor: **Bing Han** · enrollment: 64 (actual)

## Conditions studied

- Pure Red Cell Aplasia

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT03364764
- **Lead sponsor:** Bing Han
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2019-02-01
- **Final completion:** 2021-05-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364764, "Sirolimus Treatment for Refractory PRCA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03364764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*